1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
J. De Langen(The Netherlands Cancer Institute), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Naomi Veney(AstraZeneca (United States)), Sarah B. Goldberg(Yale University), Marlene Dressman(AstraZeneca (United States)), N. Hewson(AstraZeneca (United Kingdom)), Julie Maidment(AstraZeneca (United Kingdom)), Zofia Piotrowska(Global Cancer Institute), Isamu Okamoto(Kyushu University Hospital), Xiao‐Feng Le(The University of Texas MD Anderson Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Jean Lau(AstraZeneca (United States)), J.W. Goldman(University of California, Los Angeles), Jan Cosaert(AstraZeneca (United Kingdom)), B.C. Cho(Yonsei University), Helen Ambrose(AstraZeneca (United Kingdom)), Kwan-ho Tang(AstraZeneca (United States))
Cited by 7
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777